MedPath

Effect of White Light on Fatigue Levels in Patients With Gynecological Cancer

Not Applicable
Completed
Conditions
Light; Therapy, Complications
Cancer-related Fatigue
Interventions
Other: White Light Application
Registration Number
NCT05009693
Lead Sponsor
Eskisehir Osmangazi University
Brief Summary

White light therapy is one of the non-pharmacological methods in the management of fatigue. Cancer-related fatigue (CRF) is a persistent, subjective sense of physical, emotional, and/or cognitive tiredness or burnout. It is associated with cancer or cancer treatment from the first diagnosis until the end of life that is not proportional to recent physical activity.

It was founded that 10,000 Lux bright white light administered in the morning hours reduced fatigue by 17% in patients with cancer and that the mean fatigue scores of patients decreased from 30.37 to 9.48 compared to before the light administration. According to NCCN (2020), white light of 10,000 Lux can be applied for 30-90 minutes in the morning hours to regulate sleep and manage fatigue in the post treatment period as well as in cancer patients receiving active treatment. However, studies on this subject consist of small sample groups, and more studies are needed to identify the risks and benefits of the application and to determine the optimal application time and duration. The present study was aimed to evaluate the effect of white light on the fatigue levels of patients with gynecological cancer who were treated with chemotherapy. The patients with high levels of fatigue in every dimension were selected so as to have a homogeneous group. The research hypotheses were determined as follows:

H0: White light has no effect on fatigue levels in patients with gynecological cancer.

H1: White light reduces fatigue levels in patients with gynecological cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
72
Inclusion Criteria
  • had a normal state of consciousness,
  • had no communication disorders, did not work in the night shift,
  • had a general fatigue level score of ≥1 according to the Brief Fatigue Inventory
Exclusion Criteria
  • had natural/artificial lenses,
  • used medication that causes photosensitivity (tetracycline, doxycycline, nalidixic acid, voriconazole, amiodarone, hydrochlorothiazide, naproxen, piroxicam, chlorpromazine)
  • had a change in their treatment plan in the last 6 weeks were not included in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
white light intervention groupWhite Light ApplicationBetween the second and the eighth days of the application phase, the patients in the intervention group were administered a standard white light at 10,000 Lux intensity by an independent nurse (RA1) in their home environment using a Litebook Elite light source (The Litebook Company Ltd., Medicine Hat, AB). The distance between the light source and the patient's face was set at 50 cm, and the intensity of the light for each patient was checked using a Lux Meter. The intervention was applied between 07:00 and 10:00 in the morning for 30 minutes without interruption, and it was continued for seven successive days. The light application procedure was followed based on the previous studies on oncology patients. The second and third evaluations of the fatigue status of patients were completed on the 9th and 21st days.
Primary Outcome Measures
NameTimeMethod
White light changes general fatigue scoresgeneral fatigue levels of patients on 0., 9. and 21. days

White light changes general fatigue levels in patients with gynecological cancer

Secondary Outcome Measures
NameTimeMethod
White light changes activity fatigue scoresactivity fatigue levels of patients on 0., 9. and 21. days

White light changes activity fatigue levels in patients with gynecological cancer

Trial Locations

Locations (1)

Eskisehir Osmangazi University Faculty of Medicine

🇹🇷

Eskisehir, Turkey

© Copyright 2025. All Rights Reserved by MedPath